{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:46:08Z","timestamp":1789688768684,"version":"4.0.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T00:00:00Z","timestamp":1529366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T00:00:00Z","timestamp":1529366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Persistent alopecia (PA) after docetaxel has been recently described. The aim of our study is to establish the incidence and characteristics of PA following adjuvant docetaxel for breast cancer (BC) and to test the ability of scalp cooling in prevention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>BC patients receiving adjuvant chemotherapy followed or not by endocrine therapy (and a control group receiving only endocrine therapy) were interviewed in a single institution at 1.5 to 5\u00a0years following primary diagnosis searching for PA. A confirmatory prevalence study was later performed in other two institutions. Finally, a prevention study using prophylactic scalp cooling (PSC) with ELASTO-GEL hypothermia caps in patients receiving adjuvant docetaxel was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the initial prevalence study (492 patients), minor forms of PA (grade 1) were recorded with all chemotherapy regimens and aromatase inhibitors. Patients receiving docetaxel regimens at cumulative dose (CD)\u2009\u2265\u2009400 mmg\/m\n                      <jats:sup>2<\/jats:sup>\n                      presented a significantly higher prevalence of grades 1 PA (33\u201352%) and 2 PA (5\u201312%). Prevalence of grade 2 PA with docetaxel CD\u2009\u2265\u2009400 mmg\/m\n                      <jats:sup>2<\/jats:sup>\n                      was confirmed in two other institutions. Overall, grade 2 PA was seen in 10.06% (95% CI 7.36\u201313.61) of 358 patients with docetaxel regimens reaching CD\u2009\u2265\u2009400 mmg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , but not in patients with lower docetaxel CD, other chemotherapy regimens, or endocrine therapy alone. In prevention trial, no grade 2 PA occurred among 116 patients receiving adjuvant docetaxel (\u2265\u2009400 mmg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) and PSC followed-up after a 96 months median time. PSC was well tolerated. No scalp relapses were seen among 30 patients (22% of all inclusions) having disease relapse.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Adjuvant treatment with docetaxel (CD\u2009\u2265\u2009400 mmg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) is associated with a significant rate of grade 2 PA, leading to wearing a wig, in around 10% of patients. This toxicity was completely prevented with scalp cooling. Clinical Trial Reference: NCT00515762.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-018-4855-2","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T10:01:25Z","timestamp":1529402485000},"page":"627-634","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling"],"prefix":"10.1007","volume":"171","clinical-trial-number":[{"clinical-trial-number":"nct00515762","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9237-3231","authenticated-orcid":false,"given":"M.","family":"Mart\u00edn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. C.","family":"de la Torre-Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"L\u00f3pez-Tarruella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Pinilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Casado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Jerez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Puente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Palomero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Gonz\u00e1lez del Val","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"del Monte-Millan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Massarrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Garc\u00eda-Paredes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Garc\u00eda-S\u00e1enz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lluch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,19]]},"reference":[{"key":"4855_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/0277-5379(83)90418-2","volume":"19","author":"A Coates","year":"1983","unstructured":"Coates A, Abraham S, Kaye SB et al (1983) On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203\u2013208","journal-title":"Eur J Cancer Clin Oncol"},{"key":"4855_CR2","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0025-7125(16)30976-2","volume":"70","author":"AF Hood","year":"1986","unstructured":"Hood AF (1986) Cutaneous side effects of cancer chemotherapy. Med Clin N Am 70:187\u2013209","journal-title":"Med Clin N Am"},{"key":"4855_CR3","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/S0959-8049(00)00012-5","volume":"36","author":"P Katsimbri","year":"2000","unstructured":"Katsimbri P, Bamias A, Pavlidis N (2000) Prevention of chemotherapy-induced alopecia using an effective scalp cooling system. Eur J Cancer 36:766\u2013771","journal-title":"Eur J Cancer"},{"key":"4855_CR4","first-page":"43","volume":"7","author":"BM Baker","year":"1991","unstructured":"Baker BM, Wilson CL, Davis AL et al (1991) Busulfan\/cyclophosphamide conditioning for bone marrow transplantation may lead to failure to hair re-growth. Bone Marrow Transpl 7:43\u201347","journal-title":"Bone Marrow Transpl"},{"key":"4855_CR5","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/j.1365-2133.2005.06469.x","volume":"152","author":"A Tosti","year":"2005","unstructured":"Tosti A, Piraccini BM, Vicenzi C et al (2005) Permanent alopecia after busulfan chemotherapy. Br J Dermatol 152:1056\u20131058","journal-title":"Br J Dermatol"},{"key":"4855_CR6","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1200\/JCO.2003.02.063","volume":"21","author":"C Henderson","year":"2003","unstructured":"Henderson C, Berry D, Demetri G et al (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976\u2013983","journal-title":"J Clin Oncol"},{"key":"4855_CR7","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1056\/NEJMoa043681","volume":"352","author":"M Martin","year":"2005","unstructured":"Martin M, Pienkowski T, Mackey J et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302\u20132313","journal-title":"N Engl J Med"},{"key":"4855_CR8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/01.coc.0000026486.56886.18","volume":"26","author":"J Childress","year":"2003","unstructured":"Childress J, Lokich J (2003) Cutaneous hand and foot toxicity associated with cancer chemotherapy. Am J Clin Oncol 26:435\u2013436","journal-title":"Am J Clin Oncol"},{"key":"4855_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/annonc\/mdg050","volume":"14","author":"AM Minisini","year":"2003","unstructured":"Minisini AM, Tosti A, Sobrero AF et al (2003) Taxane-induced nail changes: incidence, clinical presentation and outcome. Ann Oncol 14:333\u2013337","journal-title":"Ann Oncol"},{"issue":"1 suppl","key":"4855_CR10","first-page":"740","volume":"23","author":"EA Calhoun","year":"2005","unstructured":"Calhoun EA, Welshman E, Brown S (2005) Taxane-induced alopecia: a historical review of patients with ovarian or breast cancer treated with paclitaxel, docetaxel or paclitaxel poliglumex. J Clin Oncol 23(June 1 suppl):740 s","journal-title":"J Clin Oncol"},{"key":"4855_CR11","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1200\/JCO.2001.19.2.314","volume":"19","author":"JM Nabholtz","year":"2001","unstructured":"Nabholtz JM, Mackey JR, Smylie M (2001) Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 19:314\u2013321","journal-title":"J Clin Oncol"},{"issue":"suppl1","key":"4855_CR12","first-page":"s116","volume":"100","author":"SM Sedlacek","year":"2006","unstructured":"Sedlacek SM (2006) Persistent significant alopecia (PSA) from adjuvant docetaxel after doxorubicin\/cyclophosphamide (AC) chemotherapy in women with breast cancer. Breast Cancer Res Treat 100(suppl1):s116","journal-title":"Breast Cancer Res Treat"},{"key":"4855_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.det.2006.01.012","volume":"24","author":"WE Roberts","year":"2006","unstructured":"Roberts WE (2006) Dermatologic problems of older women. Dermatol Clin 24:271\u2013280","journal-title":"Dermatol Clin"},{"key":"4855_CR14","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1093\/annonc\/mdt170","volume":"24","author":"A Rossi","year":"2013","unstructured":"Rossi A, Iorio A, Scali E et al (2013) Aromatase inhibitors induce \u201cmale pattern hair loss\u201d in women? Ann Oncol 24:1710\u20131711","journal-title":"Ann Oncol"},{"key":"4855_CR15","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/annonc\/mds095","volume":"23","author":"N Kluger","year":"2012","unstructured":"Kluger N, Jacot W, Frouin E (2012) Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil\/epirubicin\/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. Ann Oncol 23:2879\u20132884","journal-title":"Ann Oncol"},{"key":"4855_CR16","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jaad.2016.12.027","volume":"76","author":"A Fonia","year":"2017","unstructured":"Fonia A, Cota C, Setterfield F, Goldberg LJ, Fenton DA, Stefanato CM (2017) Permanent alopecia in patients with breast cancer after taxane chemotherapy and adjuvant hormonal therapy: clinicopathologic findings in a cohort of 10 patients. J Am Acad Dermatol 76:948\u2013957","journal-title":"J Am Acad Dermatol"},{"key":"4855_CR17","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1001\/jama.2016.21038","volume":"317","author":"HS Rugo","year":"2017","unstructured":"Rugo HS, Klein P, Melin SA et al (2017) Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer. JAMA 317:606\u2013614","journal-title":"JAMA"},{"key":"4855_CR18","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1001\/jama.2016.20939","volume":"317","author":"J Nangia","year":"2017","unstructured":"Nangia J, Wang T, Osborne C et al (2017) Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer. The SCALP randomized clinical trial. JAMA 317:596\u2013605","journal-title":"JAMA"},{"key":"4855_CR19","doi-asserted-by":"publisher","first-page":"4424","DOI":"10.1200\/JCO.2005.15.651","volume":"23","author":"F Scott\u00e9","year":"2005","unstructured":"Scott\u00e9 F, Tourani JM, Banu E et al (2005) Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 23:4424\u20134429","journal-title":"J Clin Oncol"},{"issue":"2","key":"4855_CR20","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10549-011-1453-y","volume":"128","author":"J Lemieux","year":"2011","unstructured":"Lemieux J, Desbiens C, Hogue JC (2011) Breast cancer scalp metastasis as first metastatic site after scalp cooling: two cases of occurrence after 7- and 9-year follow-up. Breast Cancer Res Treat 128(2):563\u2013566","journal-title":"Breast Cancer Res Treat"},{"key":"4855_CR21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10549-017-4185-9","volume":"163","author":"HS Rugo","year":"2017","unstructured":"Rugo HS, Mellin SA, Voigt J (2017) Scalp cooling with adjuvant\/neoadjuvant chemotherapy for breast cancer and risk of scalp metastases: systematic review and meta-analysis. Breast Cancer Res Treat 163:199\u2013205","journal-title":"Breast Cancer Res Treat"}],"updated-by":[{"DOI":"10.1007\/s10549-018-4883-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000}}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-018-4855-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-018-4855-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-018-4855-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T11:48:44Z","timestamp":1628596124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-018-4855-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,19]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["4855"],"URL":"https:\/\/doi.org\/10.1007\/s10549-018-4855-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,19]]},"assertion":[{"value":"11 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2018","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original publication of the article, Table\u00a01 was published with incorrect caption and values. The Table\u00a01 with corrected caption and values is given in this Correction.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare that the experiments comply with the current laws of the country in which it was performed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}